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Abstract Phospholipase D (PLD) is involved in various aspects
of cellular function. Two isoforms, PLD1 and PLD2, have been
identified. PLD1, which has two splicing variants, is regulated by
various factors, including ADP-ribosylation factor (ARF). We
here show that both variants of PLD1 are predominantly
localized to late endosomes and lysosomes, but not to the Golgi
apparatus or endoplasmic reticulum in contrast to earlier studies.
Furthermore, PLD1s show significant colocalization with an
ARF6 mutant defective in GTP binding. The data suggest that
PLD1, under the regulation of ARF6, plays a role in the function
of endosomes and lysosomes.
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1. Introduction
Phospholipase D (PLD) catalyzes hydrolysis of phosphati-
dylcholine to generate phosphatidic acid (PA) and choline. PA
itself and its hydrolytic product, diacylglycerol, function as
second messengers (for review, see [1^4]). Two mammalian
PLD genes (PLD1 and PLD2) have recently been identi¢ed;
PLD1 has two splicing variants, PLD1a and PLD1b. PLD1 is
activated by several protein factors, including members of the
ADP-ribosylation factor (ARF) family, while PLD2 is insen-
sitive to the PLD1 activators and constitutively active in the
presence of phosphatidylinositol 4,5-bisphosphate ([5^7], re-
viewed in [3,4]).
ARF was originally identi¢ed as a cofactor of the ADP-
ribosyltransferase activity of the cholera toxin (for review, see
[8]). Thereafter, ARF was shown to regulate a number of
vesicular tra⁄cking events, such as the formation of Golgi-
derived COP I-coated and AP-1/clathrin-coated vesicles
([9,10]; reviewed in [11,12]). ARF may also regulate the endo-
some-endosome fusion event [13]. Of six mammalian ARFs
(ARF1^ARF6) so far identi¢ed, ARF1, which has been most
extensively studied, plays a pivotal role in vesicular tra⁄cking
(for reviews, see [11,12]). Another well characterized member
of the ARF family is ARF6. Unlike ARF1, it appears to
function in the plasma membrane and the endosomal system
[14^16]. An ARF6 mutant restricted to the GTP-bound form,
ARF6(Q67L), is localized to the plasma membrane and de-
creases the rate of transferrin uptake, while a GDP-bound
mutant, ARF6(T27N), is localized to endosomal compart-
ments and inhibits recycling of endocytosed materials to the
cell surface [14^16].
Since ARF1, as well as ARF3, was ¢rst identi¢ed as a PLD
activator [17,18], PLD is believed to be involved in the ARF-
dependent vesicular tra⁄cking. This notion is supported by
the reports that ARF-dependent PLD activity is present in
Golgi-enriched membranes and COP I binds to membranes
upon production of PA by exogenous PLD [19,20]. In con-
trast, Brown et al. have demonstrated that green £uorescent
protein (GFP)-tagged PLD1b overexpressed in RBL-2H3 cells
localizes to secretory granules and lysosomes, but not to Golgi
apparatus [21]. Analysis by Colley et al. of subcellular local-
ization of epitope-tagged PLD1a revealed that it localizes to
perinuclear regions including the endoplasmic reticulum (ER),
Golgi apparatus and endosomes [6]. Although they did not
unequivocally identify the subcellular compartment where
PLD1a localizes, these observations, taken together, raise
the possibility that an ARF-sensitive PLD isozyme of Golgi-
enriched membranes is PLD1a. To examine this possibility, in
this study we determined and compared the subcellular local-
ization of PLD1a expressed in several types of mammalian
cells with that of PLD1b. The results obtained show that
both PLD1 variants are localized almost exclusively to late
endosomes and lysosomes, but not to the Golgi apparatus
or ER. Furthermore, PLD1 was found to be colocalized
with ARF6(N122I), a mutant defective in GTP binding, sug-
gesting that ARF6 is a physiological activator of PLD1.
2. Materials and methods
2.1. Plasmid construction
cDNAs of mouse PLD1b and human PLD1a were obtained by
PCR of mouse brain and human HL60 cell cDNAs, respectively,
using primers synthesized based on the published nucleotide se-
quences. Expression vectors for N-terminally hemagglutinin (HA)-
tagged mouse PLD1b (pcDNA3-HA-PLD1b) and FLAG-tagged hu-
man PLD1a (pTB-FL-PLD1a) were constructed by subcloning of the
cDNAs into pcDNA3-HAN and pTB701-FL, respectively. The con-
struction of an expression vector for C-terminally HA-tagged ARF6
(pcDNA3-ARF6-HA) was described previously [22]. Q67L and N122I
mutations of ARF6 were introduced into the ARF6 cDNA by a PCR-
based strategy using mutagenic primers.
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2.2. Antibodies
Polyclonal rabbit anti-rat lamp-1 antibody was kindly provided by
Dr. K. Akasaki (Fukuyama University, Fukuyama, Japan) [23].
Monoclonal mouse anti-rat transferrin receptor (Tfn-R) antibody
(OX-26) was purchased from Chemicon International. Monoclonal
mouse anti-mannosidase II (Man II) antibody (53FC3) was from
Berkeley Antibody Co. Monoclonal rat (3F10) and mouse (12CA5)
antibodies against the HA epitope were from Boehringer Mannheim.
Monoclonal mouse anti-FLAG M2 antibody was from Eastman
Kodak Co. All secondary antibodies were from Jackson Immuno-
Research Laboratories.
2.3. Immuno£uorescence analysis
Clone 9 rat hepatocytes, monkey kidney Vero cells or HeLa cells
grown in wells of 8-well Lab-Tek-II chamber slides (Nunc) were trans-
fected with either pcDNA3-HA-PLD1b or pTB-FL-PLD1a alone, or
in combination with an expression vector for either wild type or
mutant ARF6 using TransIT LT1 (PanVera Corp.) or FuGENE
6 (Boehringer Mannheim) transfection reagent. The cells were cul-
tured for 24^48 h and then processed for indirect immuno£uorescence
analysis as described previously [22,24,25]. The stained cells were ob-
served with a laser-scanning confocal microscope (TCS-NT, Leica
Lasertechnik).
3. Results and discussion
To determine and compare the subcellular localization of
the PLD1a with that of PLD1b, we transiently expressed epit-
ope-tagged PLD1a and PLD1b in several types of mammalian
cells, including NRK, Vero and HeLa cells. As shown in Fig.
1, FLAG-tagged PLD1a and HA-tagged PLD1b were colo-
calized to large vesicular structures scattered in the cytoplasm
in all the examined cells. Thus, there is no di¡erence in the
localization between the PLD1 splicing variants. Furthermore,
the observations that PLD1 is localized to similar vesicular
structures in many cell types exclude a possibility that tran-
sient overexpression of PLD1 resulted in its aberrant subcel-
lular localization.
To unequivocally identify the intracellular compartment
where PLD1 locates, cells expressing HA-tagged PLD1b
were double-stained with antibodies to marker proteins for
various organelles. When the HA-PLD1b-expressing cells
were double-stained with antibodies to the HA epitope and
Man II (a resident Golgi integral membrane protein), the
staining for HA-PLD1b was not superimposed on that for
Man II (Fig. 2A,AP). Furthermore, when the cells were treated
with brefeldin A (BFA), which causes disintegration of the
Golgi structure following dissociation of the COP I coat
from Golgi membranes [26], the PLD1b localization was not
altered, whereas Man II (Fig. 2B,BP) and L-COP (data not
shown), a component of the COP I coat, were redistributed
throughout the cytoplasm. These observations indicate that
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Fig. 1. Subcellular localization of PLD1a and PLD1b. NRK (A,
AP), Vero (B, BP) or HeLa (C, CP) cells transiently cotransfected
with pcDNA3-HA-PLD1b and pTB-FL-PLD1a were ¢xed, permea-
bilized, and double-stained with monoclonal rat anti-HA (A, B, C)
and monoclonal mouse anti-FLAG M2 (AP, BP, CP) antibodies fol-
lowed by FITC-labeled anti-rat and Cy3-labeled anti-mouse IgGs.
Fig. 2. Sensitivity to BFA of PLD1. NRK cells transiently trans-
fected with pcDNA3-HA-PLD1b were incubated for 30 min in the
presence (B, BP) or absence (A, AP) of 5 Wg/ml BFA, ¢xed, permea-
bilized, and double-stained with monoclonal rat anti-HA (A, B) and
monoclonal mouse anti-Man II (AP, BP) antibodies followed by
FITC-labeled anti-rat and Cy3-labeled anti-mouse IgGs.
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PLD1 does not localize to the Golgi apparatus. We also dou-
ble-stained the HA-PLD1b-transfected cells for HA and pro-
tein disul¢de isomerase (an ER marker) but failed to observe
their colocalization (data not shown), suggesting that PLD1
does not localize to the ER. Because the large vesicular struc-
tures containing PLD1 were reminiscent of lysosomes and
endosomes, we then examined if PLD1 was colocalized with
Tfn-R (an early and late endosomal marker) and lamp-1 (a
marker for late endosomes and lysosomes). As shown in Fig.
3, a partial but signi¢cant overlap was observed between the
staining for HA-PLD1b and Tfn-R (panels A and AQ). Fur-
thermore, the staining for HA-PLD1b was found to be largely
superimposed on that for lamp-1 (panels B and BQ). These
observations clearly demonstrate that PLD1 is predominantly
localized to late endosomes and lysosomes but not to the
Golgi apparatus or ER, which is consistent with the previous
report with GFP-tagged PLD1b [21].
Ktistakis et al. have previously reported that Golgi-enriched
membrane fractions separated by sucrose gradients contain a
high level of ARF-sensitive PLD activity [19], although we
could not detect PLD1 on the Golgi apparatus. This discrep-
ancy may be explained by a possible contamination of endo-
somes and lysosomes in the Golgi-enriched fraction. Alterna-
tively, it is possible that there is an additional ARF-sensitive
PLD isozyme(s) that is di¡erent from the already identi¢ed
ARF-sensitive PLD1.
Because ARF6 is known to function in the recycling endo-
cytic pathway [14^16] and, as well as ARF1 and ARF3, is
able to activate PLD1 in vitro [17,18,27], it is possible to
speculate that ARF6 physiologically functions as a PLD1 ac-
tivator. To compare the localization of ARF6 with that of
PLD1, cells were transiently cotransfected with expression
vectors for FLAG-tagged PLD1a and HA-tagged ARF6 or
its mutant, and double-stained with anti-FLAG and anti-HA
antibodies. Because it is di⁄cult to raise antibodies that spe-
ci¢cally recognize ARF6 due to the high sequence similarity
between ARF isoforms (ARF1^ARF6), we [22] and others
[15] have used HA-tagged ARF6. As shown in Fig. 4A,AP,
wild type ARF6, unlike PLD1a, was distributed throughout
the cytoplasm. When HA-tagged ARF6(N122I) was coex-
pressed with PLD1a, the vesicular staining pattern for
PLD1a was almost identical to that for ARF6(N122I) (Fig.
4C,CP). This is in good agreement with the previous report
that ARF6(T27N) localizes to endosome/lysosomes [14^16].
Both ARF6(N122I) and ARF6(T27N) are thought to be
GTP-binding-defective mutants, because it has been shown
that equivalent ARF1 mutants, ARF1(N126I) and
ARF1(T31N), are defective in GTP binding and similarly in-
hibit vesicular transport [28]. A GTP-bound active mutant,
ARF6(Q67L), was localized to cytoplasm and the cell periph-
ery and was not signi¢cantly colocalized with PLD1 (Fig.
4B,BP). We also analyzed the localization of wild type
ARF1 and its mutants equivalent to ARF6(N122I) and
ARF6(Q67L), but neither of them colocalized with PLD1
(data not shown).
Colocalization of PLD1 with the GTP-binding-defective
mutant, ARF6(N122I), seems to be consistent with previous
reports showing that another GTP-binding-defective mutant
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Fig. 3. Localization of PLD1 to late endosomes/lysosomes. NRK cells transiently transfected with pcDNA3-HA-PLD1b were ¢xed, permeabi-
lized, and double-stained with a combination of monoclonal rat anti-HA (A) and monoclonal mouse anti-Tfn-R (AP) antibodies followed by
FITC-labeled anti-rat and Cy3-labeled anti-mouse IgGs or a combination of monoclonal mouse anti-HA (B) and polyclonal rabbit anti-lamp-1
(BP) antibodies followed by FITC-labeled anti-mouse and Cy3-labeled anti-rabbit IgGs. Overlays are shown in the right panels.
K. Toda et al./FEBS Letters 442 (1999) 221^225 223
ARF6(T27N) signi¢cantly colocalized with Tfn-R [14^16].
Localization of wild type ARF6 was, however, di¡erent
from that of ARF6(N122I) and was distributed throughout
the cytoplasm. At present, there is no clear explanation for the
di¡erence in subcellular localization between wild type ARF6
and its GTP-binding-defective mutant. Nevertheless, colocali-
zation of PLD1 and the GTP-binding-defective ARF6 mu-
tant, taken together with the observations that ARF6 func-
tions in the recycling endocytic pathway [14^16] and is able to
activate PLD in vitro [27], leads us to speculate that upon cell
activation ARF6 activates PLD on lysosomes and/or endo-
somes, which, in turn, regulates the function of endosomes
and lysosomes. This idea is consistent with the report by
Brown et al. that activation of PLD1b overexpressed in
RBL-2H3 cells by cross-linking of IgE receptors correlates
well with the release of lysosomal contents [21].
Brown et al. have shown that stimulation of RBL-2H3 cells
by cross-linking of IgE receptors causes translocation of GFP-
tagged PLD1b to the plasma membrane [21], and Caumont et
al. have shown that stimulation of chroma⁄n cells causes
translocation of ARF6 to the plasma membrane fractions
and concomitant activation of PLD in the plasma membrane
fractions [29]. In the present study, however, we failed to show
translocation of PLD1 from endosomes/lysosomes to the plas-
ma membrane in cells expressing ARF6(Q67L), a constitu-
tively active mutant. A possible explanation for the apparent
discrepancy is that the constitutively active ARF6 mutant is
directly located to the cell periphery without being trapped on
endosomes/lysosomes where PLD1 is present, and thus unable
to cause translocation and activation of PLD1. Cycling be-
tween GDP-bound inactive and GTP-bound active states may
be required for ARF6 to activate and recruit PLD1 to the
plasma membrane. To address this issue, experiments are
under way in our laboratory.
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